Kat2a loss (NULL) results in enhanced cell-to-cell transcriptional variability and progressive loss of leukemia stem cells (LSCs) transformed with the KMT2A-MLLT3 (MLL-AF9) gene fusion (12). The gene discussed is MLLT3; the disease is leukemia.